| Paul Hudson took the helm at Sanofi from Olivier Brandicourt this week, as the French drugmaker looks to pivot from primary care and make the most of its recent buyouts. Formerly president of Novartis’ pharma business, Hudson joins Sanofi during an upswing: though sales dropped in 2018, the company’s second-quarter sales grew 4.1% year-over-year, in part due to its Genzyme rare disease unit. He also aims to accelerate Sanofi’s digital work—not just in R&D, but sales and operations, too. But first, he’s setting out to meet as many of his new employees as he can. | |
|
Featured Story | | | Tuesday, September 3, 2019 Paul Hudson's starting his Sanofi CEO career with a barnstorming tour to meet as many employees as possible over the next few weeks. Back at headquarters, it'll be up to the helmsman to extend Sanofi's turn toward growth and take care of "all the small things that matter," analysts said. |
|
|---|
|
| This week's sponsor is FiercePharmaMarketing. | |  | |
Top Stories Of The Week Tuesday, September 3, 2019 Vertex Pharmaceuticals is jumping into diabetes. The cystic fibrosis specialist is snapping up Semma Therapeutics and its stem cell-based diabetes treatments for $950 million in an all-cash deal slated to close in the fourth quarter. Wednesday, September 4, 2019 The clock is ticking down for the 400 workers at a Novartis plant put on the block last year as the company cuts costs to finance new therapies. There is some hope for the U.K. site, however, with half a dozen companies taking a look. Tuesday, September 3, 2019 Bayer has hired Johnson & Johnson’s former business development chief Marianne De Backer, Ph.D., as its new head of business development and licensing of its pharma division. Wednesday, September 4, 2019 Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv before going on to acquire them outright once a preclinical candidate is identified. Friday, August 30, 2019 Novartis laid out $16 billion for GlaxoSmithKline’s oncology portfolio in 2015 and spent much of the last four years laboring to make Arzerra a success. It hasn’t been lucky yet, but hopes fresh phase 3 data will help it move into multiple sclerosis. Tuesday, September 3, 2019 AstraZeneca’s diabetes med Farxiga is still looking for the cardiovascular label updates its SGLT2 competitors already bear. But as of this weekend, it has new data that could help the entire class—and even pressure heart medicines outside the class, too. Wednesday, September 4, 2019 Schrödinger’s platform aims to predict how strongly a potential drug will bind and affect a target protein with the goal of reducing the number of compounds that need to be synthesized before settling on a lead candidate. Tuesday, September 3, 2019 People with traumatic brain injuries can develop long-lasting secondary disorders after the initial blow. Scientists at the New Jersey Institute of Technology hope to stop the process with a self-assembling peptide hydrogel. Wednesday, September 4, 2019 Consumers think less of the pharma industry than ever before if a new poll is any indication. Pharma unseated the federal government to win the dubious honor of last place in an annual Gallup poll that asks Americans for their views on 25 industries. Resources Sponsored by: Patheon, by Thermo Fisher Scientific Avoid potential risks to the patient as well as costly interruptions during development. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Frenova Want to be sure your renal research protocol design is fit for the real world? Sponsored by: Recro Gainesville Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities? Sponsored by: Baxter BioPharma Solutions Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
